Health Canada
www.hc-sc.gc.ca
Common menu bar links
Institutional links
About Health Canada
Access to Information Requests Completed - July 2010
This content was archived on June 24, 2013.
Archived Content
Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.
The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. Requests such as those that did not result in the release of any records or that contain primarily personal information are not posted.
If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.
Acronyms and Descriptions
- ACAN
- Advance Contract Award Notice
- AER
- Adverse Reaction Report (Adverse Event)
- ANDS
- Abbreviated New Drug Submission
- ATI
- Access to Information
- CFL
- Compact fluorescent lamp / light
- DIN
- Drug Identification Number
- EMF
- Electric and Magnetic Fields
- HPFB-I
- Health Products and Food Branch Inspectorate
- ID
- Identification
- MG / Mg / mg
- Milligram(s)
- MHPD
- Marketed Health Products Directorate
- NDS
- New Drug Submission
- NHP
- Natural Health Product(s)
- NHPD
- Natural Health Products Directorate
- NOC
- Notice of Compliance
- NPN
- Natural Product Number
- preNDS / pre-NDS
- Pre-NDS (New Drug Submission) Meeting
- QP
- Question Period
- SNDS
- Supplement to a New Drug Submission
- SOS
- Standing Offer Solicitation
- TPD
- Therapeutic Products Directorate
- UV
- Ultraviolet
Completed Requests
| Request # | Request text |
|---|---|
| A-2007-00641 | All documentation pertaining to correspondence between Health Canada and non-governmental organizations and any anti-smoking groups or advocates for more stringent controls over the tobacco industry, for the period of 2000 to present (Oct 5, 2007). Include only those documents which contain an advocacy position, or a direct reference to an advocacy position. |
| A-2008-00022 | Briefing book prepared for the appearance of the Minister of Health at the Standing Committee on Health on June 6, 2006. Briefing books presented for each appearance on that date. Request limited to specific QP notes |
| A-2008-00040 | Internal analyses, reports prepared by consultants between Health Canada and Environment Canada between January 1, 2001 and December 31, 2007 on the pollution actually and potentially caused by ethanol production and use. |
| A-2008-00105 | All documentation pertaining to an exploratory study prepared by, or on behalf of, Health Canada, regarding discount cigarette smokers in Ontario and Québec. This study included consumers of discount brands as well as contraband and smuggled tobacco. The study included the involvement of Murray Kaiserman, and was to have been completed by the end of the 2006-2007 fiscal year. |
| A-2008-00125 | Any records of Health Canada that refers to the names of any Health Canada staff working on the BC Supreme court case of PHS Community Society vs Attorney General of Canada from April 21, 2008 to present Any document or collection of documents of Health Canada that refer to the PHS Community Services Society (PHS) and the Vancouver Area Network of Drug Users (VANDU) being used as a brief, backgrounder, information file, resource document, collection, etc for any Health Canada staff working on the PHS Community Services Society vs Attorney General of Canada BC Supreme Court Case. Include published material and news articles that you have on file. |
| A-2008-00212 | A list of all ministerial correspondence, briefing notes, 48 hours turn around, QP notes, prepared for the Minister for the period of March 1, 2008 to June 2, 2008. |
| A-2008-00503 | All records given to Health Minister Tony Clement & between Health Canada and Industry (including but not limited to, product associations, and individual companies, or interested individuals - including but not limited to Consumer Groups regarding the implementation of the new product safety legislation announced by the Federal Government on April 8, 2008. Include records dating from January 1, 2007 to April 8, 2008, inclusively. |
| A-2008-01024 | Complete documentation for the Risk Management program, which is briefly outlined on page 5 of the current approved Product Monograph (dated June 27, 2008) for TRAMACET. Provide the "progress reports" that have been sent to Health Canada from the ongoing drug abuse surveillance program, as required by the Product Monograph. |
| A-2009-00108 | All documents relating of referring to requests for exemptions pursuant to section 56 of the Controlled Drugs and Substances Act. I seek only materials related to exemption requests made on the basis of religious and/or spiritual use of controlled substances (whatever the formal basis of the requests: i.e., if a request is made on the basis of scientific, medical or public interest grounds but the genesis of the request is related to religious or spiritual practice or use of the substance, it falls into the parameters of my request). |
| A-2009-00116 | All regulatory submission related correspondence, all clinical data, all chemistry data, reviewer's notes and any other related information for CO ETIDROCAL, DIN 02263866, Manufactured by Cobalt Pharmaceuticals Inc. |
| A-2009-00251 | All minutes of Toy Committee, from September 1, 2008 to May 22, 2009. |
| A-2009-00339 | Information regarding the drug product, Twinject 0.3mg auto-Injector (DIN: 02247310) and 0.15mg auto-Injector (by Paladin Laboratories Inc. Regarding the approval process: Internal Health Canada reviewer notes, external communication between Health Canada officers or reviewers and the DIN owner. |
| A-2009-00527 | Copy of TPD Reviewer's Report for: Seroquel 25mg (DIN 02236951) Quetiapine fumarate NOC Dated 1997-12-02. |
| A-2009-00539 | The lab report relating to the investigation into the following Shoe Information: Name: Finroin - 24 Description: Two Tone Brown Leather Product Code:11-5-2 72813529 Company: ALDO Lab Technician: Pierre Maurice Damas Health Canada Rep: Rosa Parks |
| A-2009-00686 | All documents and test results, corrective action related to a study currently underway at Health Canada on "UV radiation and EMF emission levels from CFLs" Study to be completed in early fall. Three reports : Ultraviolet Radiation Emissions from Compact Fluorescent Lights, Hazard Evaluation Report. Report on Health Canada Survey of Electric and Magnetic Fields from Compact Fluorescent Lamps. Report on Health Canada Survey of Ultraviolet Radiation and Electric and Magnetic Fields from Compact Fluorescent Lamps. |
| A-2009-00784 | Copies of the following records for Bexxar (tositumomab and iodine | 131 tositumomab) manufactured by GlaxoSmithKline for the period January 1, 2003 to December 31, 2008: Reviewer's Notes and other information related to the clinical, non clinical and quality (chemistry and manufacturing) review of the original NDS and any subsequent sNDSs. Information Requests/Clarifaxes issued to the sponsor and the respective responses during the review of the NDS and any subsequent sNdSs. Copies of preNDS meeting briefing package(s), slides and meeting minutes. |
| A-2009-00805 | All regulatory correspondence includes product licence application, safety and efficacy information, quality information, information request notices and responses, processing deficiency notices and responses, record of decision, reviewer's notes for: Product Name: Centrum Materna NPN: 80001842 Name of Licensee: Wyeth Consumer Healthcare Inc. |
| A-2009-00959 | Reviewer's comments (Notes and Report), and correspondence with Health Canada regarding PROCYTOX, submission Control # 080233. |
| A-2009-01079 | Requesting a copy of all reviewer reports (e.g. Pharmaceutical Safety and Efficacy Assessment Template (PSEAT), bioequivalence studies etc) for all stages of review for the NDS or SNDS that supported the approval of Oxycontin. The relevant approval dates (NOC issued) are January 4, 1996 (DIN: 02202441, 02202468, 02202476, 02202484), December 16, 2002 (DIN: 02246902), September 23, 2004 (DIN: 02258129) and March 4, 2009 (DIN: 02323192, 02323206, 02323214, 02323222). |
| A-2009-01288 | ACAN / Solicitation #1000100722 please provide the sole source documentation more specifically, a copy of the contract (including rates) and briefing notes. |
| A-2009-01290 | All information regarding these offers including total points scores for each successful supplier, rates offered by each supplier for the term of the standing offer, and annual spent per supplier on the following SOS's and ACAN: Standing Offer Solicitation # 1000092541 (Issued through Health Canada-ON). |
| A-2009-01303 | All information that was submitted to Health Canada that led to the approval of the ANDS for the product PMS Cholestyramine Light PWD 4 G/5 G (DIN 00890960) by Pharmascience Inc., including modules 1 and 2. |
| A-2009-01425 | Product Licence submission in its entirety including the product licence application form, label text, evidence summary report, references, safety summary report, animal tissue form(s), quality summary report and all the associated information request notices and response of: Product Name: Now Silica Complex 500 mg Licence Number: 80006601 Licence Holder: Now Foods |
| A-2009-01431 | Product Licence submission in its entirety including the product licence application form, label text, evidence summary report, references, safety summary report, animal tissue form(s), quality summary report and all the associated information request notices and response of: Product Name: Greens+ (Natural mixed Berry, Natural Tangerine) Licence Number: 80010538 Licence Holder: Genuine Health |
| A-2009-01440 | Product Licence submission in its entirety including the product licence application form, label text, evidence summary report, references, safety summary report, animal tissue form(s), quality summary report and all the associated information request notices and response of: Product Name: Dioscorea Villosa, Wild Yam Root Licence Number: 80004371 Licence Holder: Natures Formulae Health Products Ltd |
| A-2009-01441 | Product Licence submission in its entirety including the product licence application form, label text, evidence summary report, references, safety summary report, animal tissue form(s), quality summary report and all the associated information request notices and response of: Product Name: Wild Yam Tincture Licence Number: 80010961 Licence Holder: St. Francis Herb Farm Incorporated |
| A-2009-01448 | Copy of all documents and correspondence between company below and Health Canada regarding product NPN requests et related NPNs: Product Name: Ongles & Cheveux (Nails & Hair) NPN: 80003089 Licence Holder: Vitaminol Inc. |
| A-2009-01476 | Information (original submission documentation, correspondence and reviewer's comments) for the following product: Product Names: Iscador M Serie Liquid, Iscador P Serie Liquid and Iscador Q Serie Liquid Licence number: NPN 02232606 Licence holder : Weleda The licence was issued by NHPD (Health Canada on June 30, 2009). |
| A-2010-00035 | Approved labelling and prescribing information for Restoralax DIN: 02318164, by Schering-Plough Canada Inc. |
| A-2010-00053 | Please provide copies of all documents held by your Department showing the list(s) of all contracts over $10,000 granted by your organization for various types of services and computer equipment from January 1, 2000 to date, April 8, 2010. The documents must show the name of each firm, the value of each contract, the type of contract for services and computer equipment, the date and the year of each contract. |
| A-2010-00072 | Copies of all reports, analyses, and other correspondence (including marginal notations & attached "post-it notes") regarding all inspections and investigations carried out under the new HPFB-I Clinical Trial Inspection Framework. |
| A-2010-00079 | Copies of all complaints and /or subsequent reports or documents concerning an incident at SFBC Anapharm. Date range September 2005 to present (April 20, 2010). |
| A-2010-00097 | All memoranda prepared for the Minister dealing with Quebec's proposed Health Deductible, contained in the provincial budget of 2010-11. Period of March 20, 2010 to present (April 23, 2010). |
| A-2010-00218 | Please provide any document from Health Canada or its agencies stating the concentration of cadmium in children's jewellery following the Health Canada evaluation completed in March 2010. |
| A-2010-00231 | Original adverse reaction reports by a health professional /layperson received by MHPD for: YASMIN - AER No: 000336652 |
| A-2010-00232 | Original adverse reaction reports by a health professional /layperson received by MHPD for: MIRENA - AER No: 000335909 |
| A-2010-00233 | Original adverse reaction reports by a health professional /layperson received by MHPD for: MAGNEVIST - AER No: 000336594 |
| A-2010-00234 | Original adverse reaction reports by a health professional /layperson received by MHPD for: LEVITRA - AER No: 000336906 |
| A-2010-00235 | Original adverse reaction reports by a health professional /layperson received by MHPD for: CIPRO - AER No: 000336890 |
| A-2010-00256 | All call-ups processed by this institution in the National Capital Region under the terms of any standing offer and/or supply arrangement for Temporary Help Services during the period of May 2010. |
| A-2010-00260 | Original adverse reaction reports by a health professional /layperson received by MHPD for: Yasmin - AER No: 000337961 |
| A-2010-00261 | Original adverse reaction reports by a health professional /layperson received by MHPD for: AVELOX & AVELOX IV - AER No: 000337490, 000337581, 000337977, 000338301, 000338440 |
| A-2010-00262 | Original adverse reaction reports by a health professional /layperson received by MHPD for: CIPRO - AER No: 000338608 |
| A-2010-00263 | Original adverse reaction reports by a health professional /layperson received by MHPD for: DIANE-35 - AER No: 000338528, 000338641 |
| A-2010-00264 | Original adverse reaction reports by a health professional /layperson received by MHPD for: MAGNEVIST - AER No: 000338317 |
| A-2010-00265 | Original adverse reaction reports by a health professional /layperson received by MHPD for: MIRENA - AER No: 000337717, 000337855, 000338843 |
| A-2010-00280 | Serious adverse reactions reported with CIPRALEX - AER No: 000331185 |
| A-2010-00281 | Serious adverse reactions reported with CIPRALEX - AER No: 000331914 |
| A-2010-00282 | Serious adverse reactions reported with CIPRALEX - AER No: 000332526 |
| A-2010-00283 | Serious adverse reactions reported with CIPRALEX - AER No: 000332899 |
| A-2010-00284 | Serious adverse reactions reported with CIPRALEX - AER No: 000334722 |
| A-2010-00285 | Serious adverse reactions reported with CIPRALEX - AER No: 000335455 |
| A-2010-00286 | Serious adverse reactions reported with CELEXA - AER No: 000331359 |
| A-2010-00287 | Serious adverse reactions reported with CELEXA - AER No: 000331732 |
| A-2010-00289 | Serious adverse reactions reported with CELEXA - AER No: 000334019 |
| A-2010-00290 | Serious adverse reactions reported with CLOPIXOL - AER No: 000332360 |
| A-2010-00302 | All documents such as business impact studies showing actual and/or estimated costs to practitioners and businesses subject to the NHP Regulations. |
| A-2010-00337 | Adverse Drug Reaction reports for suspected drug PANTOLOC (pantoprazole sodium) Report ID: 000336390 |
| A-2010-00338 | Adverse Drug Reaction reports for suspected drug Alvesco and Omnaris (ciclesonide). Reports ID: 000335936, 00038915, 000338073 |
| A-2010-00339 | Adverse Drug Reaction reports for suspected drug Tecta (pantoprazole magnesium) Report ID: 000335970, 000337178, 000337201, 000338000, 000340056 |
| A-2010-00352 | Expense accounts and travel expenses reimbursed to Germain Tremblay by your organization. For 2009-2010 fiscal year.. |
| A-2010-00358 | Original adverse reaction reports by a health professional /layperson received by MHPD for: AVELOX - AER No: 000338835, 000338879, 000339277, 000340165, 000340169, 000340271, 000340283, 000340336, 000340337, 000340446, 000340561, 000340601 |
| A-2010-00359 | Original adverse reaction reports by a health professional /layperson received by MHPD for: YASMIN - AER No: 000339479, 000339595, 000340659 |
| A-2010-00360 | Original adverse reaction reports by a health professional /layperson received by MHPD for: ADALAT XL - AER No: 000340531 |
| A-2010-00361 | Original adverse reaction reports by a health professional /layperson received by MHPD for: CIPRO - AER No: 000339600 |
| A-2010-00362 | Original adverse reaction reports by a health professional /layperson received by MHPD for: CIPRO - AER No: 000338826, 000338853 |
| A-2010-00363 | Original adverse reaction reports by a health professional /layperson received by MHPD for: CLIMARA - AER No: 000338831 |
| A-2010-00364 | Original adverse reaction reports by a health professional /layperson received by MHPD for: DIANE-35 - AER No: 000338953 |
| A-2010-00365 | Original adverse reaction reports by a health professional /layperson received by MHPD for: FLUDARA - AER No: 000339607 |
| A-2010-00366 | Original adverse reaction reports by a health professional /layperson received by MHPD for: MAGNEVIST - AER No: 000339254, 000339834 |
| A-2010-00367 | Original adverse reaction reports by a health professional /layperson received by MHPD for: MIRENA - AER No: 000340473 |
| A-2010-00368 | Provide the number of Special Authorization Program (SAP) authorizations for: Dacogen (decitabine) ESAI from June 5-11, 2010 |
| A-2010-00378 | Provide copies of original submission forms used in reporting the following Adverse Reaction Reports to MHPD: Product: Vidaza MHPD Reference# 000336201 |
| A-2010-00381 | Provide the number of Special Authorization Program (SAP) authorizations for: Dacogen (decitabine) ESAI from June 12-18, 2010 |
| A-2010-00401 | A listing of the ATI requests submitted to Health Canada for the period of May 1-31, 2010. |
| A-2010-00409 | Provide the number of Special Authorization Program (SAP) authorizations for: Dacogen (decitabine) ESAI from June 19-25, 2010 |
| A-2010-00411 | Copies of the approved labelling (outer carton label, inner label and package insert) for LYPRININ (NPN 80012063) |
| A-2010-00413 | A detailed copy of adverse drug reaction for: DICETEL (pinaverium bromide) tablets. Case # 000326353, 000332047, 000330421 |
| A-2010-00417 | A detailed copy of adverse drug reaction for: LIPIDIL (fenofibrate). Case # 000326486, 000331690 |
| A-2010-00423 | Provide the number of Special Authorization Program (SAP) authorizations for: Dacogen (decitabine) ESAI from June 26 - July 2, 2010 |
| A-2010-00426 | Adverse Drug Reaction Report received by the Canada Vigilance Program with the corresponding Canada Vigilance On-line Database AER Number: 000321359 |
| A-2010-00427 | Adverse Drug Reaction Report received by the Canada Vigilance Program with the corresponding Canada Vigilance On-line Database AER Number: 000321656 |
| A-2010-00428 | Adverse Drug Reaction Report received by the Canada Vigilance Program with the corresponding Canada Vigilance On-line Database AER Number: 000324393 |
| A-2010-00429 | Adverse Drug Reaction Report received by the Canada Vigilance Program with the corresponding Canada Vigilance On-line Database AER Number: 000327672 |
| A-2010-00430 | Adverse Drug Reaction Report received by the Canada Vigilance Program with the corresponding Canada Vigilance On-line Database AER Number: 000328909 |
| A-2010-00454 | All Callups processed by this institution in the National Capital Region under the terms of any standing offer and/or supply arrangement for Temporary Help Services during the period: June 2010. |
| A-2010-00457 | Provide the number of Special Authorization Program (SAP) authorizations for: Dacogen (decitabine) ESAI from July 3-9, 2010 |
| A-2010-00484 | Provide the number of Special Authorization Program (SAP) authorizations for: Dacogen (decitabine) ESAI from July 10-16, 2010 |
